158 related articles for article (PubMed ID: 30067967)
1. mTORC1 Upregulation Leads to Accumulation of the Oncometabolite Fumarate in a Mouse Model of Renal Cell Carcinoma.
Drusian L; Nigro EA; Mannella V; Pagliarini R; Pema M; Costa ASH; Benigni F; Larcher A; Chiaravalli M; Gaude E; Montorsi F; Capitanio U; Musco G; Frezza C; Boletta A
Cell Rep; 2018 Jul; 24(5):1093-1104.e6. PubMed ID: 30067967
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.
Ashrafian H; O'Flaherty L; Adam J; Steeples V; Chung YL; East P; Vanharanta S; Lehtonen H; Nye E; Hatipoglu E; Miranda M; Howarth K; Shukla D; Troy H; Griffiths J; Spencer-Dene B; Yusuf M; Volpi E; Maxwell PH; Stamp G; Poulsom R; Pugh CW; Costa B; Bardella C; Di Renzo MF; Kotlikoff MI; Launonen V; Aaltonen L; El-Bahrawy M; Tomlinson I; Pollard PJ
Cancer Res; 2010 Nov; 70(22):9153-65. PubMed ID: 20978192
[TBL] [Abstract][Full Text] [Related]
3. Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion.
Sudarshan S; Shanmugasundaram K; Naylor SL; Lin S; Livi CB; O'Neill CF; Parekh DJ; Yeh IT; Sun LZ; Block K
PLoS One; 2011; 6(6):e21037. PubMed ID: 21695080
[TBL] [Abstract][Full Text] [Related]
4. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.
Isaacs JS; Jung YJ; Mole DR; Lee S; Torres-Cabala C; Chung YL; Merino M; Trepel J; Zbar B; Toro J; Ratcliffe PJ; Linehan WM; Neckers L
Cancer Cell; 2005 Aug; 8(2):143-53. PubMed ID: 16098467
[TBL] [Abstract][Full Text] [Related]
5. mTORC1-driven accumulation of the oncometabolite fumarate as a potential critical step in renal cancer progression.
Drusian L; Boletta A
Mol Cell Oncol; 2019; 6(1):1537709. PubMed ID: 30788416
[TBL] [Abstract][Full Text] [Related]
6. The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling.
Sullivan LB; Martinez-Garcia E; Nguyen H; Mullen AR; Dufour E; Sudarshan S; Licht JD; Deberardinis RJ; Chandel NS
Mol Cell; 2013 Jul; 51(2):236-48. PubMed ID: 23747014
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite.
Perez M; Bak DW; Bergholtz SE; Crooks DR; Arimilli BS; Yang Y; Weerapana E; Linehan WM; Meier JL
J Biol Chem; 2020 Sep; 295(39):13410-13418. PubMed ID: 32820045
[TBL] [Abstract][Full Text] [Related]
8. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.
Ge X; Li M; Yin J; Shi Z; Fu Y; Zhao N; Chen H; Meng L; Li X; Hu Z; Zhao X; Guo H; Qian X
Mol Cell; 2022 Apr; 82(7):1249-1260.e7. PubMed ID: 35216667
[TBL] [Abstract][Full Text] [Related]
9. UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer.
Yang Y; Valera VA; Padilla-Nash HM; Sourbier C; Vocke CD; Vira MA; Abu-Asab MS; Bratslavsky G; Tsokos M; Merino MJ; Pinto PA; Srinivasan R; Ried T; Neckers L; Linehan WM
Cancer Genet Cytogenet; 2010 Jan; 196(1):45-55. PubMed ID: 19963135
[TBL] [Abstract][Full Text] [Related]
10. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
[TBL] [Abstract][Full Text] [Related]
11. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC.
Gupta S; Swanson AA; Chen YB; Lopez T; Milosevic D; Kipp BR; Leibovich BC; Thompson RH; Herrera-Hernandez L; Cheville JC; Jimenez RE
Hum Pathol; 2019 Sep; 91():114-122. PubMed ID: 31299266
[TBL] [Abstract][Full Text] [Related]
12. Renal disease in tuberous sclerosis complex: pathogenesis and therapy.
Lam HC; Siroky BJ; Henske EP
Nat Rev Nephrol; 2018 Nov; 14(11):704-716. PubMed ID: 30232410
[TBL] [Abstract][Full Text] [Related]
13. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
14. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.
Gan B; Lim C; Chu G; Hua S; Ding Z; Collins M; Hu J; Jiang S; Fletcher-Sananikone E; Zhuang L; Chang M; Zheng H; Wang YA; Kwiatkowski DJ; Kaelin WG; Signoretti S; DePinho RA
Cancer Cell; 2010 Nov; 18(5):472-84. PubMed ID: 21075312
[TBL] [Abstract][Full Text] [Related]
15. Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition.
Sciacovelli M; Gonçalves E; Johnson TI; Zecchini VR; da Costa AS; Gaude E; Drubbel AV; Theobald SJ; Abbo SR; Tran MG; Rajeeve V; Cardaci S; Foster S; Yun H; Cutillas P; Warren A; Gnanapragasam V; Gottlieb E; Franze K; Huntly B; Maher ER; Maxwell PH; Saez-Rodriguez J; Frezza C
Nature; 2016 Aug; 537(7621):544-547. PubMed ID: 27580029
[TBL] [Abstract][Full Text] [Related]
16. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration.
Muller M; Guillaud-Bataille M; Salleron J; Genestie C; Deveaux S; Slama A; de Paillerets BB; Richard S; Benusiglio PR; Ferlicot S
Mod Pathol; 2018 Jun; 31(6):974-983. PubMed ID: 29410489
[TBL] [Abstract][Full Text] [Related]
17. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
[TBL] [Abstract][Full Text] [Related]
18. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
19. A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer.
Yang Y; Valera V; Sourbier C; Vocke CD; Wei M; Pike L; Huang Y; Merino MA; Bratslavsky G; Wu M; Ricketts CJ; Linehan WM
Cancer Genet; 2012; 205(7-8):377-90. PubMed ID: 22867999
[TBL] [Abstract][Full Text] [Related]
20. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
